Discovery of 3-arylcoumarin-tetracyclic tacrine hybrids as multifunctional agents against Parkinson's disease

ACS Medicinal Chemistry Letters

Volumn 5, Issue 10, 2014, Pages 1099-1103

  Sashidhara, Koneni V ^a   Modukuri, Ram K ^a   Jadiya, Pooja ^a   Rao, K Bhaskara ^a   Sharma, Tanuj ^a   Haque, Rizwanul ^a   Singh, Deependra Kumar ^a   Banerjee, Dibyendu ^a   Siddiqi, Mohammad Imran ^a   Nazir, Aamir ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

3 Arylcoumarin; C. elegans; Parkinson's disease; reactive oxygen species; tetracyclic tacrine; synuclein

Indexed keywords

3 ARYLCOUMARIN TETRACYCLIC TACRINE DERIVATIVE; ALPHA SYNUCLEIN; DONEPEZIL; DOPAMINE; LEVODOPA; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; TACRINE DERIVATIVE; TRANSCRIPTION FACTOR DAF 16; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CAENORHABDITIS ELEGANS; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; TRANSGENIC ORGANISM;

EID: 84908013710     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500222g     Document Type: Article

References (33)

1. Obeso, J. A.; Rodriguez-Oroz, M. C.; Goetz, C. G.; Marin, C.; Kordower, J. H.; Rodriguez, M.; Hirsch, E. C.; Farrer, M.; Schapira, A. H.; Halliday, G. Missing pieces in the Parkinson's disease puzzle. Nat. Med. 2010, 16, 653-661.
2. Spillantini, M. G.; Schmidt, M. L.; Lee, V. M.; Trojanowski, J. Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839-840.
3. Lee, F. J.; Liu, F.; Pristupa, Z. B.; Niznik, H. B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 2001, 15, 916-926.
4. Olanow, C. W.; Obeso, J. A.; Stocchi, F. Continuous dopaminereceptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol. 2006, 5, 677-687.
5. Lewitt, P. A. Levodopa for the treatment of Parkinson's disease. N. Engl. J. Med. 2008, 359, 2468-2476.
6. Abbott, A. Levodopa: the story so far. Nature 2010, 466, S6-S7.
7. Meissner, W. G.; Frasier, M.; Gasser, T.; Goetz, C. G.; Lozano, A.; Piccini, P.; Obeso, J. A.; Rascol, O.; Schapira, A.; Voon, V.; Weiner, D. M.; Tison, F.; Bezard, E. Priorities in Parkinson's disease research. Nat. Rev. Drug Discovery 2011, 10, 377-393.
8. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
9. Cavalli, A.; Bolognesi, M. L.; Minarini, A.; Rosini, M.; Tumiatti, V.; Recanatini, M.; Melchiorre, C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51, 347-372.
10. Venugopala, K. N.; Rashmi, V.; Odhav, B. Review on natural coumarin lead compounds for their pharmacological activity. Biomed. Res. Int. 2013, 2013, 963248.
11. Piazzi, L.; Rampa, A.; Bisi, A.; Gobbi, S.; Belluti, F.; Cavalli, A.; Bartolini, M.; Andrisano, V.; Valenti, P.; Recanatini, M. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2 H-2-chr omenone (AP2238) inhibits both acetylcholinesterase and acetylcho-linesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J. Med. Chem. 2003, 46, 2279-2282.
12. Abdelhafez, O. M.; Amin, K. M.; Ali, H. I.; Maher, T. J.; Batran, R. Z. Dopamine release and molecular modeling study of some coumarin derivatives. Neurochem. Int. 2011, 59, 906-912.
13. Matos, M. J.; Pérez-Cruz, F.; Vazquez-Rodriguez, S.; Uriarte, E.; Santana, L.; Borges, F.; Olea-Azar, C. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins. Bioorg. Med. Chem. 2013, 21, 3900-3906.
14. Yang, Y. J.; Lee, H. J.; Huang, H. S.; Lee, B. K.; Choi, H. S.; Lim, S. C.; Lee, C. K.; Lee, M. K. Effects of scoparone on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells. J. Neurosci. Res. 2009, 87, 1929-1937.
15. Van Laar, T.; De Deyn, P. P.; Aarsland, D.; Barone, P.; Galvin, J. E. Effects of cholinesterase inhibitors in Parkinson's disease dementia: a review of clinical data. CNS Neurosci. Ther. 2011, 17, 428-441.
16. Marco-Contelles, J.; León, R.; de los Ríos, C.; García, A. G.; López, M. G.; Villarroya, M. New multipotent tetracyclic tacrines with neuroprotective activity. Bioorg. Med. Chem. 2006, 14, 8176-8185.
17. León, R.; de los Ríos, C.; Marco-Contelles, J.; Huertas, O.; Barril, X.; Luque, F. J.; López, M. G.; García, A. G.; Villarroya, M. New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorg. Med. Chem. 2006, 16, 7759-7769.
18. Sashidhara, K. V.; Kumar, M.; Khedgikar, V.; Kushwaha, P.; Modukuri, R. K.; Kumar, A.; Gautam, J.; Singh, D.; Sridhar, B.; Trivedi, R. Discovery of coumarin-dihydropyridine hybrids as bone anabolic agents. J. Med. Chem. 2013, 56, 109-122.
19. Sashidhara, K. V.; Palnati, G. R.; Avula, S. R.; Kumar, A. Efficient and general synthesis of 3-aryl coumarins using cyanuric chloride. Synlett 2012, 23, 611-621.
20. Khan, A. T.; Lal, M.; Ali, S.; Khan, M. M. One-pot threecomponent reaction for the synthesis of pyran annulated heterocyclic compounds using DMAP as a catalyst. Tetrahedron Lett. 2011, 52, 5327-5332.
21. Marco-Contelles, J.; Pérez-Mayoral, E.; Samadi, A.; Carreiras, M. C.; Soriano, E. Recent advances in the Friedländer reaction. Chem. Rev. 2009, 109, 2652-2671.
22. Bodhicharla, R.; Nagarajan, A.; Winter, J.; Adenle, A.; Nazir, A.; Brady, D.; Vere, K.; Richens, J.; O'Shea, P.; Bell, D. R.; de Pomerai, D. Effects of α-synuclein overexpression in transgenic Caenorhabditis elegans strains. CNS Neurol. Disord. Drug Targets 2012, 11, 965-975.
23. Vistbakka, J.; VanDuyn, N.; Wong, G.; Nass, R. C. elegans as a genetic model system to identify Parkinson's disease-associated therapeutic targets. CNS Neurol. Disord. Drug Targets 2012, 11, 957-964.
24. Shukla, V.; Phulara, S. C.; Yadav, D.; Tiwari, S.; Kaur, S.; Gupta, M. M.; Nazir, A.; Pandey, R. Iridoid compound 10-O-trans-p-coumaroylcatalpol extends longevity and reduces α synuclein aggregation in Caenorhabditis elegans. CNS Neurol. Disord. Drug Targets 2012, 11, 984-992.
25. Jadiya, P.; Khan, A.; Sammi, S. R.; Kaur, S.; Mir, S. S.; Nazir, A. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease. Biochem. Biophys. Res. Commun. 2011, 413, 605-610.
26. Dias, V.; Junn, E.; Mouradian, M. M. The role of oxidative stress in Parkinson's disease. J. Parkinson's Dis. 2013, 3, 461-491.
27. Jadiya, P.; Nazir, A. Environmental toxicants as extrinsic epigenetic factors for Parkinsonism: Studies employing transgenic C. elegans model. CNS Neurol. Disord. Drug Targets 2012, 11, 976-983.
28. Bargmann, C. I.; Hartwieg, E.; Horvitz, H. R. Odorant-selective genes and neurons mediate olfaction in C. elegans. Cell 1993, 74, 515-527.
29. Kaur, S.; Sammi, S. R.; Jadiya, P.; Nazir, A. RNAi of cat-2, a putative tyrosine hydroxylase, increases alpha synuclein aggregation and associated effects in transgenic C. elegans. CNS Neurol. Disord. Drug Targets 2012, 11, 387-394.
30. Chiang, W. C.; Tishkoff, D. X.; Yang, B.; Wilson-Grady, J.; Yu, X.; Mazer, T.; Eckersdorff, M.; Gygi, S. P.; Lombard, D. B.; Hsu, A. L. C. elegans SIRT6/7 homolog SIR-2.4 promotes DAF-16 relocalization and function during stress. PLoS Genet. 2012, 8, e1002948.
31. Ruzza, P.; Siligardi, G.; Hussain, R.; Marchiani, A.; Islami, M.; Bubacco, L.; Delogu, G.; Fabbri, D.; Dettori, M. A.; Sechi, M.; Pala, N.; Spissu, Y.; Migheli, R.; Serra, P. A.; Sechi, G. Ceftriaxone blocks the polymerization of α-synuclein and exerts neuroprotective effects in vitro. ACS Chem. Neurosci. 2014, 5, 30-33.
32. Hess, B.; Kutzner, C.; Van der Spoel, D.; Lindahl, E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 2008, 4, 435-447.
33. Huang, H. J.; Chen, H. Y.; Lee, C. C.; Chen, C. Y. Computational design of apolipoprotein e4 inhibitors for Alzheimer's disease therapy from traditional chinese medicine. Biomed. Res. Int. 2014, 2014, 452625.